Protagonist Therapeutics Set to Join S&P SmallCap 600
Express News | Protagonist Therapeutics To Join S&P SmallCap 600, Effective Prior To Opening Of Trading On July 3
Encore Wire (NASDAQ:WIRE) Is Very Good At Capital Allocation
Are You Looking for a Top Momentum Pick? Why Encore Wire (WIRE) Is a Great Choice
Encore Wire, the Prysmian Buyout and Next Picks
Prysmian Obtains US Antitrust Clearance for Encore Wire Acquisition
Express News | Italy's Prysmian -Transaction Remains Subject to Approval of Encore Wire’s Shareholders Representing at Least a Majority of Outstanding Shares
Encore Wire's Go-Shop Period Ends With No Interest From Potential Buyers
Encore Wire Ticks Lower After Disclosing No Bids in Go-shop for Prysmian sale
Encore Wire Keeps Cash Dividend at $0.02 a Share, Payable July 19 to Holders of Record July 5
Press Release: Encore Wire Announces Cash Dividend
UPDATE 1-Italy's Prysmian Posts Higher Q1 Margin, Sees FY Results at Upper End of Forecasts
Encore Wire's Merger Turmoil: High Stakes With a $146.54 Million Risk
Analysts' Opinions Are Mixed on These Industrial Goods Stocks: Encore Wire (WIRE) and Crane Company (CR)
Encore Wire Beats Top-line and Bottom-line Estimates; Initiates FY24 and Beyond Capex Outlook
Express News | Encore Wire Says Remain Focused On Long-Term Opportunities For Its Business As It Continues To Address Near-Term Challenges
Earnings Flash (WIRE) ENCORE WIRE CORPORATION Reports Q1 Revenue $632.7M
Express News | Encore Wire Corp - Expect Total Capital Expenditures to Range From $130 - $150 Mln in 2024, $130 - $150 Mln in 2025, and $100 - $120 Mln in 2026
Express News | Encore Wire Q1 Sales USD 632.7 Million
Express News | Encore Wire Q1 Net Income USD 63.277 Million